THE ROLE OF PROGESTERONE IN PREVENTING PRETERM LABOR: A SYSTEMATIC REVIEW

Saima Gul; Arifa Khan; Roma Zubair; Naqeeb Ullah; Bushra Imtiaz Ali; Shawwal Amjad; Fakhra Syed

doi:10.46903/gjms/23.2.1832

THE ROLE OF PROGESTERONE IN PREVENTING PRETERM LABOR: A SYSTEMATIC REVIEW

Saima Gul, Arifa Khan, Roma Zubair, Naqeeb Ullah, Bushra Imtiaz Ali, Shawwal Amjad, Fakhra Syed

Abstract

Progesterone may help prevent premature delivery in high-risk pregnancies, according to research. Progestogens have been studied extensively and are still being studied. In women with a high-risk profile, such as those who have a history of spontaneous preterm delivery or a short cervical length (CL) on transvaginal ultrasound (TVU), prophylactic progesterone use may lower the chance of PTB. This is a systematic review investigating the effect of progesterone in preventing preterm labor, follows the PRISMA protocol. A methodical search was conducted using multiple databases of research-based literature including PubMed, Cochrane, Google Scholar, and Web of Sciences from 2000-2024. Statistical Package for Social Sciences (SPSS) version 22 was used to sort, analyze, and present data graphically. Minimum gestational age for starting progesterone therapy to reduce the risk of preterm labour and delivery was reported as 14 weeks, while end of therapy was planned until delivery. The reported incident of pre term labour, delivery and fetal death was significantly lower in patients treated with progesterone with singleton pregnancies. Preterm delivery is still a serious issue in obstetric care, impacting mothers and newborns worldwide, having significant health and economic effects for the healthcare system, individuals, and families. Limited research exists on neonatal and long-term baby health outcomes, thus it’s uncertain if extending pregnancy leads to better outcomes. The purpose of this study was to assess the effectiveness of progesterone (vagina, Oral and intramuscular) in managing preterm labour to prevent, manage and reduce the risk of neonatal and maternal complications.

Keywords

Delivery; labor; Multiple; Pregnancy; Pre term; Progesterone; Singleton.

Full Text:

PDF

References

Fonseca EB, Damião R, Moreira DA. Preterm birth prevention. Best Pract Res Clin Obstet Gynaecol. 2020;69:40-9. https://doi.org/10.1016/j.bpobgyn.2020.09.003

Society for Maternal-Fetal Medicine Publications Committee. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice. Am J Obstet Gynecol. 2012;206(5):376-86. https://doi.org/10.1016/j.ajog.2012.03.010

World Health Organization. WHO recommendations on antenatal corticosteroids for improving preterm birth outcomes. Geneva: World Health Organization; 2022 Sep 30.

Tita AT, Rouse DJ. Progesterone for preterm birth prevention: an evolving intervention. Am J Obstet Gynecol. 2009;200(3):219-24. https://doi.org/10.1016/j.ajog.2008.12.035

Berghella V. Progesterone and preterm birth prevention: translating clinical trials data into clinical practice.

Lotfy M, Amer A, El-Boghdady A. Prophylactic use of progesterone vaginal suppository in prevention of recurrent preterm labor. Al-Azhar Med J. 2021;50(4):2715-24. https://doi.org/10.21608/amj.2021.196413

Bulletti C, Bulletti FM, Sciorio R, Guido M. Progesterone: The key factor of the beginning of life. Int J Mol Sci. 2022;23(22):14138. https://doi.org/10.3390/ijms232214138

Patil AS, Gaikwad NW, Grotegut CA, Dowden SD, Haas DM. Alterations in endogenous progesterone metabolism associated with spontaneous very preterm delivery. Hum Reprod Open. 2020;2020(2):hoaa007. https://doi.org/10.1093/hropen/hoaa007

Boelig RC, Naert MN, Fox NS, Hennessy S, Chervoneva I, Berghella V, et al. Predictors of early preterm birth despite vaginal progesterone therapy in singletons with short cervix. Am J Perinatol. 2020;37(13):1289-95. https://doi.org/10.1055/s-0040-1710008

Simons NE, Leeuw M, Van't Hooft J, Limpens J, Roseboom TJ, Oudijk MA, et al. The long‐term effect of prenatal progesterone treatment on child development, behaviour and health: a systematic review. BJOG. 2021;128(6):964-74. https://doi.org/10.1111/1471-0528.16582

Cacciamani GE, Chu TN, Sanford DI, Abreu A, Duddalwar V, Oberai A, et al. PRISMA AI reporting guidelines for systematic reviews and meta-analyses on AI in healthcare. Nat Med. 2023;29(1):14-5. https://doi.org/10.1038/s41591-022-02139-w

Meis PJ, Klebanoff M, Thom E, Dombrowski MP, Sibai B, Moawad AH, et al. Prevention of recurrent preterm delivery by 17 alpha-hydroxyprogesterone caproate. N Engl J Med. 2003;348(24):2379-85. https://doi.org/10.1056/NEJMoa035140

da Fonseca EB, Bittar RE, Carvalho MH, Zugaib M. Prophylactic administration of progesterone by vaginal suppository to reduce the incidence of spontaneous preterm birth in women at increased risk: a randomized placebo-controlled double-blind study. Am J Obstet Gynecol. 2003;188(2):419-24. https://doi.org/10.1067/mob.2003.41

Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17 alpha-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357(5):454-61. https://doi.org/10.1056/NEJMoa070641

Borna S, Sahabi N. Progesterone for maintenance tocolytic therapy after threatened preterm labour: a randomised controlled trial. Aust N Z J Obstet Gynaecol. 2008;48(1):58-63. https://doi.org/10.1111/j.1479-828X.2007.00803.x

Rai P, Rajaram S, Goel N, Gopalakrishnan RA, Agarwal R, Mehta S. Oral micronized progesterone for prevention of preterm birth. Int J Gynaecol Obstet. 2009;104(1):40-3. https://doi.org/10.1016/j.ijgo.2008.08.029

Glover MM, McKenna DS, Downing CM, Smith DB, Croom CS, Sonek JD. A randomized trial of micronized progesterone for the prevention of recurrent preterm birth. Am J Perinatol. 2011;28(5):377-81. https://doi.org/10.1055/s-0031-1274509

Combs CA, Garite T, Maurel K, Das A, Porto M, Network OC. 17-hydroxyprogesterone caproate for twin pregnancy: a double-blind, randomized clinical trial. Am J Obstet Gynecol. 2011;204(3):221.e1. https://doi.org/10.1016/j.ajog.2010.12.042

Choudhary M, Suneja A, Vaid NB, Guleria K, Faridi MM. Maintenance tocolysis with oral micronized progesterone for prevention of preterm birth after arrested preterm labor. Int J Gynaecol Obstet. 2014;126(1):60-3. https://doi.org/10.1016/j.ijgo.2014.01.019

Nelson DB, McIntire DD, McDonald J, Gard J, Turrichi P, Leveno KJ. 17-alpha Hydroxyprogesterone caproate did not reduce the rate of recurrent preterm birth in a prospective cohort study. Am J Obstet Gynecol. 2017;216(6):600.e1. https://doi.org/10.1016/j.ajog.2017.02.025

Ashoush S, El-Kady O, Al-Hawwary G, Othman A. The value of oral micronized progesterone in the prevention of recurrent spontaneous preterm birth: a randomized controlled trial. Acta Obstet Gynecol Scand. 2017;96(12):1460–6. https://doi.org/10.1111/aogs.13236

Sykes L, Bennett PR. Efficacy of progesterone for prevention of preterm birth. Best Pract Res Clin Obstet Gynaecol. 2018;52:126–36. https://doi.org/10.1016/j.bpobgyn.2018.08.006

Pacagnella RC, Mol BW, Borovac-Pinheiro A, Passini R, et al. A randomized controlled trial on the use of pessary plus progesterone to prevent preterm birth in women with short cervical length (P5 trial). BMC Pregnancy Childbirth. 2019;19:1–9. https://doi.org/10.1186/s12884-019-2513-2

Creasy RK, Gummer BA, Liggins GC. System for predicting spontaneous preterm birth. Obstet Gynecol. 1980;55(6):692–5.

Mesiano SA, Peters GA, Amini P, Wilson RA, Tochtrop GP, van Den Akker F. Progestin therapy to prevent preterm birth: history and effectiveness of current strategies and development of novel approaches. Placenta. 2019;79:46–52. https://doi.org/10.1016/j.placenta.2019.01.018

Norwitz ER, Caughey AB. Progesterone supplementation and the prevention of preterm birth. Rev Obstet Gynecol. 2011;4(2):60.

da Fonseca EB, Damião R, Moreira DA. Preterm birth prevention. Best Pract Res Clin Obstet Gynaecol. 2020;69:40–9. https://doi.org/10.1016/j.bpobgyn.2020.09.003

Meis PJ. The role of 17α-hydroxyprogesterone caproate in the prevention of preterm birth. Womens Health (Lond). 2006;2(6):819–24. https://doi.org/10.2217/17455057.2.6.819

Pacagnella RC, Silva TV, Cecatti JG, Passini R Jr, Fanton TF, et al. Pessary plus progesterone to prevent preterm birth in women with short cervixes: a randomized controlled trial. Obstet Gynecol. 2022;139(1):41–51. https://doi.org/10.1097/AOG.0000000000004634

Yadav G, Gupta S, Singh P, Kansara M, Kathuria P, Gothwal M, et al. The role of vaginal progesterone in established pre-term labor: a randomized controlled trial. J Family Med Prim Care. 2022;11(11):7042–7. https://doi.org/10.4103/jfmpc.jfmpc_884_22

Boelig RC, Schoen CN, Frey H, Gimovsky AC, Springel E, Backley S, et al. Vaginal progesterone vs intramuscular 17-hydroxyprogesterone caproate for prevention of recurrent preterm birth: a randomized controlled trial. Am J Obstet Gynecol. 2022;226(5):722.e1. https://doi.org/10.1016/j.ajog.2022.02.012

Sirisangwon R, Phupong V. Vaginal progesterone supplementation in the management of preterm labor: a randomized controlled trial. Matern Child Health J. 2021;25(7):1102–9. https://doi.org/10.1007/s10995-021-03153-z

Cheung KW, Seto MT, Ng EH. Early universal use of oral progesterone for prevention of preterm births in singleton pregnancy (SINPRO study): protocol of a multicenter, randomized, double-blind, placebo-controlled trial. Trials. 2020;21:1–7. https://doi.org/10.1186/s13063-020-4067-z

Srisutham K, Wuttikonsammakit P, Chamnan P. Efficacy of vaginal and oral progesterone after tocolytic therapy in threatened preterm labor: a 3-arm parallel-group randomized controlled trial. J Med Assoc Thai. 2021;104(5):–. https://doi.org/10.35755/jmedassocthai.2021.05.12018

Conde-Agudelo A, Rehal A, Da Fonseca E, Brizot ML, Rode L, Serra V, et al. Vaginal progesterone for the prevention of preterm birth and adverse perinatal outcomes in twin gestations with a short cervix: an updated individual patient data meta-analysis. Ultrasound Obstet Gynecol. 2022;59(2):263. https://doi.org/10.1002/uog.24839

Conde-Agudelo A, Romero R. Vaginal progesterone for the prevention of preterm birth: who can benefit and who cannot? Evidence-based recommendations for clinical use. J Perinat Med. 2023;51(1):125–34. https://doi.org/10.1515/jpm-2022-0462

Soni M, Singh V, Patel N, Singh AK, Rizvi EH. Assessment of efficacy of prophylactic administration of oral micronized progesterone in preventing preterm labor in high-risk pregnancies. Eur J Cardiovasc Med. 2023;13(1):–. https://doi.org/10.47750/pnr.2022.13.S02.56

Rouse DJ, Caritis SN, Peaceman AM, Sciscione A, Thom EA, Spong CY, et al. A trial of 17α-hydroxyprogesterone caproate to prevent prematurity in twins. N Engl J Med. 2007;357(5):454–61. https://doi.org/10.1056/NEJMoa070641

Çetingöz E, Cam C, Sakallı M, Karateke A, Celik C, Sancak A. Progesterone effects on preterm birth in high-risk pregnancies: a randomized placebo-controlled trial. Arch Gynecol Obstet. 2011;283:423–9. https://doi.org/10.1007/s00404-009-1351-2

Norman JE, Marlow N, Messow CM, Shennan A, Bennett PR, Thornton S, et al. Vaginal progesterone prophylaxis for preterm birth (the OPPTIMUM study): a multicentre, randomised, double-blind trial. Lancet. 2016;387(10033):2106–16. https://doi.org/10.1016/S0140-6736(16)00350-0

Senat MV, Porcher R, Winer N, Vayssière C, Deruelle P, Capelle M, et al. Prevention of preterm delivery by 17α-hydroxyprogesterone caproate in asymptomatic twin pregnancies with a short cervix: a randomized controlled trial. Am J Obstet Gynecol. 2013;208(3):194.e1. https://doi.org/10.1016/j.ajog.2013.01.032

Nachum Z, Paz YG, Massalha M, Wated M, Harel N, Yefet E. Vaginal progesterone for pregnancy prolongation after arrested preterm labor: a randomized clinical trial. JAMA Netw Open. 2024;7(7):e2419894. https://doi.org/10.1001/jamanetworkopen.2024.19894

Zipori Y, Bachar G, Farago N, Lauterbach R, Weissman A, Beloosesky R, et al. Vaginal progesterone treatment for the prevention of preterm birth and intrahepatic cholestasis of pregnancy: a case–control study. Eur J Obstet Gynecol Reprod Biol. 2020;253:117–20. https://doi.org/10.1016/j.ejogrb.2020.08.043

Hudic I, Szekeres-Bartho J, Vrtacnik EB, Klun IV, Brkic S, Frangez HB, et al. Progesterone induced blocking factor (PIBF) taken in early pregnancy predicts the pregnancy outcome in women undergoing in vitro fertilization procedure. J Reprod Immunol. 2020;140:103150. https://doi.org/10.1016/j.jri.2020.103150

Cathey AL, Watkins DJ, Rosario ZY, Vega CM, Mukherjee B, O’Neill MS, et al. Gestational hormone concentrations are associated with timing of delivery in a fetal sex-dependent manner. Front Endocrinol (Lausanne). 2021;12:742145. https://doi.org/10.3389/fendo.2021.742145

Kikuchi S, Kobayashi N, Watanabe Z, Ono C, Takeda T, Nishigori H, et al. The delivery of a placenta/fetus with high gonadal steroid production contributes to postpartum depressive symptoms. Depress Anxiety. 2021;38(4):422–30. https://doi.org/10.1002/da.23134

Jain V, McDonald SD, Mundle WR, Farine D. Guideline No. 398: progesterone for prevention of spontaneous preterm birth. J Obstet Gynaecol Can. 2020;42(6):806–12. https://doi.org/10.1016/j.jogc.2019.04.012

DOI: https://doi.org/10.46903/gjms/23.2.1832